Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Neuroscience

Takeda buys rights to Ovid’s soticlestat for $856 million

by Megha Satyanarayana
March 5, 2021 | A version of this story appeared in Volume 99, Issue 8

 

The structure of soticlestat.

Takeda Pharmaceutical has agreed to buy Ovid Therapeutics’ developmental seizure treatment, soticlestat, for up to $856 million, including an up-front payment of $196 million. Soticlestat, which inhibits the enzyme cholesterol 24-hydroxylase, reduced seizure frequency in a Phase 2 trial of children with rare neurological diseases. Takeda discovered the drug, then licensed it to Ovid in 2017 for development.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.